CDK6 and plasma cell myeloma: reported the design and synthesis of palbociclib-based PROTACs targeting CDK6 which induced the degradation of mutant CDK6 and effectively inhibited the proliferation of multiple myeloma (MM), leukaemia, and MCL cells.